•
Sep 30, 2019

Corcept Therapeutics Q3 2019 Earnings Report

Total Revenue
$81.5M
Previous year: $64.4M
+26.5%
EPS
$0.31
Previous year: $0.22
+40.9%
R&D Expenses
$22.8M
SG&A Expenses
$24.2M
Gross Profit
$80.1M
Previous year: $63.1M
+26.8%
Cash and Equivalents
$44.9M
Previous year: $33.9M
+32.6%
Free Cash Flow
$38.1M
Previous year: $44.5M
-14.2%
Total Assets
$367M
Previous year: $300M
+22.4%

Corcept Therapeutics

Corcept Therapeutics